$0.94
1.34% today
Nasdaq, Apr 02, 09:50 pm CET
ISIN
CA14161Y2006
Symbol
CRDL
Sector
Industry

Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock price

$0.92
-0.17 15.44% 1M
-1.01 52.24% 6M
-0.36 27.99% YTD
-0.89 49.08% 1Y
-0.59 38.96% 3Y
-0.97 51.23% 5Y
-2.82 75.37% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.01 0.64%
ISIN
CA14161Y2006
Symbol
CRDL
Sector
Industry

Key metrics

Market capitalization $75.70m
Enterprise Value $54.55m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.46
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-29.40m
Free Cash Flow (TTM) Free Cash Flow $-17.94m
Cash position $21.26m
EPS (TTM) EPS $-0.38
P/E forward negative
Short interest 2.24%
Show more

Is Cardiol Therapeutics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:

Buy
100%

Financial data from Cardiol Therapeutics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.27 0.27
50% 50%
-
-0.27 -0.27
50% 50%
-
- Selling and Administrative Expenses 19 19
67% 67%
-
- Research and Development Expense 10 10
3% 3%
-
-29 -29
33% 33%
-
- Depreciation and Amortization 0.27 0.27
50% 50%
-
EBIT (Operating Income) EBIT -29 -29
33% 33%
-
Net Profit -27 -27
29% 29%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cardiol Therapeutics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock News

Positive
Proactive Investors
about one month ago
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said that new research published in the Journal of the American College of Cardiology: Basic to Translational Science (JACBTS) supports the potential of its cannabidiol-based drug candidate CRD-38 to treat heart failure. The study, conducted by scientists at Tecnológico de Monterrey in collaboration with researchers from the DeBakey Heart and Vascula...
Neutral
GlobeNewsWire
3 months ago
Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company's lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at ...
Neutral
MarketBeat
4 months ago
Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investors with their low prices and potential for significant returns, only to fail to live up to those expectations. The world of penny stocks is also characterized by pump-and-dump and other scams, facilitated by the fact that most penny stock companies do not have an extensive history of financial re...
More Cardiol Therapeutics Inc - Ordinary Shares - Class A News

Company Profile

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its product, CardiolRx, is a pharmaceutically produced extra strength oral cannabidiol formulation that is entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Head office Canada
CEO David Elsley
Employees 22
Founded 2017
Website www.cardiolrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today